Digital Scoop India Official Platform of Digital Scoop India Featuring Latest & Best News #Articles #Bytes #Entertainment #DigitalScoopMagazine
Related Articles
As a rifleman in the Republic of Korea Marine Corps who endured harsh training as part of his national service, Kevin Choi had “no doubt” about the state of his health.
“I’ve got quite severe myopia, but I still believed I was very healthy,” Choi told CNBC Make It.
But all that changed in 2016, when he discovered he had glaucoma — a chronic, progressive eye disease caused by optic nerve damage.
While glaucoma is more common in older adults, Choi was only 26 when he was diagnosed.
By then, Choi said he had already lost half of his right eye vision, and only had about “60% to 70%” of his left eye vision left — something which could have been avoided with early detection.
But in the same year, he rose above these adversities by launching his own health-care startup, Mediwhale.
Its devices assess cardiovascular risk through the use of retinal imagery and artificial intelligence — a first of its kind, Mediwhale told Make It.
With starting capital of $5,000, he launched the startup with his ophthalmologist, Dr. Tyler Hyungtaek Rim six years ago.
Today, the company said it has raised millions from investors, with its devices approved in the EU and several countries in Asia.
Choi, who is Mediwhale’s CEO, said he is a firm believer that his diagnosis is “not a coincidence.”
As an industrial engineer by training, he started thinking of possible AI solutions that can enhance early detection of diseases.
“There must be some reason this happened to me. And I think that I could solve this myself, because I’m an engineer,” said the 31-year-old.
As a medical doctor, Rim also understood the “unmet needs” in clinical settings when it comes to the detection of cardiovascular diseases — typically done through computerized tomography scans.
“CT scans require a lot of resources and are time consuming, therefore it is a burden for both health-care providers and patients,” he added.
Long patient journey i
Choi’s own experience with “long patient journeys,” referring to the time between a patient getting in queue at a hospital to getting test results from doctors — also prompted him to design a faster alternative.
“Long patient journey is a big hurdle to get past. Even now, I feel very anxious every time I visit the hospital for glaucoma checkups … it’s a long test with a two to three hours wait [for results].”
Mediwhale claims that with just one retinal photograph per eye, it achieves the “same accuracy” in detecting cardiovascular risk as a CT scan, while delivering patient reports “within a minute.”
“It takes just a few seconds as it doesn’t require any dilation. The image is simultaneously uploaded to the cloud system upon taking and automatically analyzed by our AI,” Rim explained.
Convincing doctors
The biggest challenge that the founders faced was convincing other doctors that the eyes could really be “the window to the whole body,” said Choi.
“The eyes are the only organs in the body in which you can see blood vessels without any invasive measures,” Rim added.
“Changes in your retina’s microvascular structure … have been identified as strong predictors of blood vessel-related diseases, such as cardiovascular and kidney issues, because the changes often happen well before you may even notice certain important symptoms,” Rim explained.
What gave Mediwhale the credibility boost it needed, said Choi, was publishing research in two peer-reviewed journals that validated the use of retinal photographs as a biomarker.
Mediwhale said its technology has since been approved for use by the EU and seven countries, including the U.K., Korea and Singapore.
While the technology is still awaiting FDA clearance in the U.S., five hospitals in Arkansas have begun clinical studies using Mediwhale’s retinal scan, the company added.
To date, Mediwhale said it has raised over $5 million, and its investors include Japanese venture capital firm SBI Investment and Korea’s BNK Venture Capital.
What gave Mediwhale the credibility boost it needed, said Choi, was publishing research in two peer-reviewed journals that validated the use of retinal photographs as a biomarker.
Mediwhale said its technology has since been approved for use by the EU and seven countries, including the U.K., Korea and Singapore.
While the technology is still awaiting FDA clearance in the U.S., five hospitals in Arkansas have begun clinical studies using Mediwhale’s retinal scan, the company added.
To date, Mediwhale said it has raised over $5 million, and its investors include Japanese venture capital firm SBI Investment and Korea’s BNK Venture Capital.
But in the meantime, despite the progress and success he’s found with his business, Choi said it’s been a “humbling” experience.
“The health-care business is a very conservative one. Every conversation I have with doctors or experts … is a lesson to be learnt,” he added.
“To me, that’s the most important characteristic to have as an entrepreneur.”
